论文部分内容阅读
目的观察复方中药治疗非酒精性脂肪性肝病的疗效和作用机制。方法运用高脂饲料饮食制备非酒精性脂肪性肝病动物模型,治疗组药物灌胃,采用酶法测定血及肝组织中总胆固醇(TC)、甘油三酯(TG)、游离脂肪酸(FFA)及血中丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)的含量,观察肝组织学变化。采用反转录-聚合酶链反应(RT-PCR)测定酰基辅酶A氧化酶(AOX)的表达。结果中药高剂量组血及肝中TC、TG、FFA含量较模型组有明显降低(P<0.05);中药高剂量组ALT、AST较模型组有明显降低(P<0.05);中药治疗组肝组织脂肪变及炎症计分较模型组有明显降低(P<0.05);AOX的表达中药组和吉非贝齐组较模型组明显升高(P<0.05)。结论中药治疗非酒精性脂肪性肝病有明显疗效,可能通过激活过氧化物酶体增生物激活受体-α(PPAR-α)使AOX表达上调而改善脂肪变。
Objective To observe the efficacy and mechanism of compound Chinese herbs in the treatment of nonalcoholic fatty liver disease. Methods The animal model of non-alcoholic fatty liver disease was prepared by high-fat diet. The treatment group was intragastrically administered. The total cholesterol (TC), triglyceride (TG) and free fatty acid (FFA) were measured by enzymatic method. The contents of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in blood were observed to observe histological changes in the liver. The expression of acyl-CoA oxidase (AOX) was measured by reverse transcription-polymerase chain reaction (RT-PCR). Results The contents of TC, TG and FFA in blood and liver of high-dose group were significantly lower than those in model group (P<0.05); ALT and AST in high-dose group were significantly lower than those in model group (P<0.05); The tissue fat changes and inflammation scores were significantly lower than those in the model group (P<0.05). The expression of AOX in the Chinese medicine group and the gemfibrozil group was significantly higher than that in the model group (P<0.05). Conclusion Chinese medicine has obvious curative effect in the treatment of non-alcoholic fatty liver disease. It may be through the activation of peroxisome proliferator-activated receptor-α (PPAR-α) to increase the expression of AOX and improve steatosis.